Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma

Key facts

Sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Principal Investigator

Xiaoyu Yin, MD. PhD, MD

First Affiliated Hospital, Sun Yat-Sen University

Intervention

PDT-Deuteporfin（6 hour)(combination_product)

Enrollment

7 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2018

Study locations (4)

• The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
• The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
• Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
• Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Perihilar cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06986486
  Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
  Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• RECRUITINGNANCT06850753
  En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
  Oslo University Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT06717464
  Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGNANCT06493734
  Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
  Erasmus Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT05564403
  Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
  National Cancer Institute (NCI)
• ACTIVE NOT RECRUITINGPHASE2NCT06178588
  Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
  University of Kansas Medical Center
• RECRUITINGNANCT06125769
  LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
  Azienda Sanitaria Ospedaliera
• RECRUITINGPHASE4NCT05551299
  Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
  University of Leipzig

See all trials for Perihilar cholangiocarcinoma →